Cancer Research UK
UCL Cancer Institute is home to London's first Cancer Research UK Centre.
Our vision for the Cancer Research UK - UCL Centre is to foster world class research into the causes of cancers and why they develop, and use this knowledge to develop new drugs and therapies.
The Cancer Research UK-UCL Centre brings together researchers and clinicians from UCL and its four partner hospital trusts, known as UCL Partners (University College London Hospital NHS Foundation Trust, Great Ormond Street Hospital for Children NHS Trust, the Royal Free Hampstead NHS Trust, and Moorfields Eye Hospital NHS Foundation Trust) as well as the London School of Pharmacy and Cancer Research UK.
Our vision for cancer research at the Centre is to become world leaders in haemato-oncology, lung cancer and cancers of the nervous system. The Centre is developing therapeutic advances in cancer focused on the Centre’s specific areas of expertise, and building further research excellence in cancer types in which the Centre holds an international reputation. With our breadth of expertise in tumour immunology, immune-regulation, cancer vaccines, adoptive immunotherapy, T-cell engineering, chimeric antigen receptor (CAR)- engineered lymphocytes and vector design, we can deliver gene, cellular and immune-based cancer therapies.
Our wider vision for the Centre is to achieve Major Cancer Research UK Centre status. This will entail establishing a true partnership with Cancer Research UK to accelerate translational research by engaging the breadth of research across UCLH and partner hospitals, and to articulate a shared vision with Cancer Research UK for philanthropy and enterprise.
Our strategy for the current triennium is to develop further the research strengths of the UCL Cancer Institute and to establish multi-disciplinary interactions with other faculties and networks at UCL, together with strong research collaborations with other Centres.
As part of the London Cancer realm, the UCL Cancer Institute is well placed to formalise interactions and make further connections with institutions including The Crick, ICR, Barts Cancer Institute and King’s College London.
The Centre is arranged around three principal structures:
1. Core Resources providing core infrastructural, bioinformatics and technical expertise. Additionally these will facilitate individual peer-awarded research programmes focusing on technologies and clinical applications.
2. Multidisciplinary Groups where UCL has achieved international competitiveness, organised along thematic lines bringing researchers together working in related areas across a range of cancer types.
3. Cancer Programmes focusing on developing translational research in cancers in which UCL has an international reputation.
Through the CRUK- funded clinical and non-clinical PhD studentship programme, the Centre will support the next generation of cancer researchers through their academic and clinical careers.
The Centre will develop a clear research engagement strategy to raise the profile of cancer research within the UCL Cancer Institute, London and nationwide.
UCL Cancer Institute
Paul O'Gorman Building
University College London
72 Huntley Street